[Clinical practice guidelines for meropenem therapy in neonatal sepsis (2024)]
- PMID: 38436306
- PMCID: PMC10921874
- DOI: 10.7499/j.issn.1008-8830.2309059
[Clinical practice guidelines for meropenem therapy in neonatal sepsis (2024)]
Abstract
Meropenem is one of the most widely used special-grade antimicrobial agents in the treatment of neonatal sepsis. However, its irrational use has led to an increasingly severe problem of bacterial multidrug resistance. The guideline was developed following standardized methods and procedures, and provides 12 recommendations specifically addressing 9 clinical issues. The recommendations cover various aspects of meropenem use in neonates, including timing of administration, recommended dosage, extended infusion, monitoring and assessment, antimicrobial adjustment strategies, treatment duration, and treatment strategies for carbapenem-resistant Enterobacteriaceae infections. The aim of the guideline is to provide evidence-based recommendations and guidance for the rational use of meropenem in neonates with sepsis.
美罗培南是新生儿脓毒症治疗中使用最为广泛的特殊级别抗菌药物之一,但其不合理应用导致细菌多重耐药问题日益严峻。该指南遵循规范的制订方法与流程,针对9个临床问题形成了12条推荐意见,内容涵盖新生儿美罗培南的使用时机、推荐剂量、延长输注、监测与评估、抗菌药物调整方案、治疗疗程以及碳青霉烯耐药肠杆菌目细菌感染的治疗策略,以期为美罗培南在新生儿脓毒症患儿中的合理使用提供循证证据与用药建议。.
Keywords: Clinical practice guideline; Meropenem; Neonate; Sepsis.
Conflict of interest statement
本指南的制订受到了国家重点研发计划(2021YFC2700700)和国家自然科学基金项目(72304008)的资助,其资金主要用于指南制订会议和制订组专家的劳务支出。本指南形成的推荐意见未受到资助的影响。指南制订组所有成员均声明无利益冲突。
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
